Physiologas Technologies closes fourth tranche of its Series A to build Japan's first home haemodialysis machine
What's the deal? Physiologas TechnologiesDealroom has a profile for this one. Try Dealroom →, a university spinout based in Sagamihara, Japan, has closed a fourth tranche of its Series A round. The funding came from Hokuhoku CapitalDealroom has a profile for this one. Try Dealroom → and individual investors via a third-party share allocation. The company is building a compact home haemodialysis machine — a device that doesn't yet exist in Japan.
Founded in 2020 out of Kitasato University, Physiologas is developing a system that recirculates dialysis fluid inside the device by adsorbing and removing uraemic toxins. The technology is based on research by Kenichi Kokubo, an associate professor at Kitasato who also serves as the startup's chief technology officer. As of late May, the company's stated capital stood at roughly ¥350M (about $2.4M).
The fresh funds will go towards design, prototyping, and pre-clinical testing — including electrical safety, electromagnetic compatibility, and biocompatibility tests.
Why now? Japan has 340,000 patients with end-stage renal failure, most of whom travel to clinics three times a week for four-hour sessions. Home haemodialysis is clinically superior and far less burdensome, yet only about 800 patients in the country use it. The reason is simple: no machine has been purpose-built for home use. Patients must install bulky clinic-grade equipment requiring plumbing and complex water-quality management.
Physiologas wants to change that by offering a smaller, safer, home-specific device that could eliminate hospital visits and enable more frequent treatment.
What could go wrong? Medical device development is slow and capital-intensive. Physiologas still faces pre-clinical trials, regulatory approval, and manufacturing scale-up — each a potential bottleneck. The home dialysis market in Japan remains tiny, and patient adoption will depend on reimbursement policies and physician buy-in. Competing solutions from larger medtech firms could also emerge.
The signal: With total stated capital of just $2.4M after four Series A tranches, Physiologas illustrates how lean Japan's university-spinout medtech ecosystem remains — and how regional investment funds like Hokuhoku Capital are stepping in to fill early-stage gaps that mainstream venture capital often ignores. The prize is substantial: 340,000 clinic-dependent dialysis patients represent a captive domestic market waiting for a home-use alternative that, remarkably, still does not exist.
Read more: prtimes.jp
